Price movement over the last 24 hours
Global X Artificial Intelligence & Technology ETF vs Humana Inc — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $62.53, while Humana Inc trades at $396.3 (market cap $47.38B). The key difference: Humana Inc pays a 0.9% dividend while Global X Artificial Intelligence & Technology ETF pays none, and Humana Inc is trading nearer its 52-week high, Global X Artificial Intelligence & Technology ETF nearer its low. Which is the better fit depends on your goals.
| AIQ | HUM | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.14 | $409.42 |
52-Week Low | $43.28 | $163.67 |
Market Cap | — | $47.38B |
Enterprise Value | — | $56.42B |
Dividend Yield | — | 0.9% |
Signals from Pluang's Aura AI — not financial advice
AIQ trades at $63.84, up 3.22% with a neutral technical signal. The ETF shows strong momentum with moving averages indicating bullish sentiment while oscillators remain neutral. Recent performance highlights include turning $10,000 into $13,400 over six months, outperforming broader market indices. The fund has gained attention for its AI-focused strategy amid expanding market interest beyond mega-cap technology stocks.
The outlook remains positive as AI adoption accelerates, though valuations require monitoring. Key risks include thematic ETF concentration and fee structure considerations. Institutional interest in AI infrastructure spending supports long-term growth potential, but market volatility around AI stock rotations presents near-term challenges.
Humana (HUM) trades at $394.62, down 0.54% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. Revenue growth is strong, reaching $129.66B in 2025, though net income margin has compressed to 0.82%. Recent news highlights expansion through Medicaid contracts and divestitures, alongside legal scrutiny over healthcare costs. The stock shows resilience with consistent earnings beats but faces profitability pressures.
Outlook is mixed: bullish technicals and revenue growth support upside, but margin erosion and legal risks pose challenges. Analysts are cautious with a consensus hold rating and price target of $315, below the current price. Investors should weigh solid fundamentals against regulatory and competitive headwinds for balanced risk-reward assessment.
Trailing returns across standard periods
AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.
Read more on AIQ →Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →